Evidence map›Paper›PMID 37334379›Full record

ArticleFrontiers in immunology2023

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.

William D Tolbert, Yaozong Chen, Lulu Sun, Mehdi Benlarbi, Shilei Ding, Rohini Manickam, Emily Pangaro, Dung N Nguyen, Suneetha Gottumukkala, Marceline Côté and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

William D TolbertInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Yaozong ChenInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Lulu SunLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States.
Mehdi BenlarbiCentre de recherche du Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Shilei DingCentre de recherche du Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Rohini ManickamInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Emily PangaroInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Dung N NguyenInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Suneetha GottumukkalaInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Marceline CôtéDepartment of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada.
Frank J GonzalezLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, United States.
Andrés FinziCentre de recherche du Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Zahra R TehraniDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Mohammad M SajadiDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Marzena PazgierInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Uniformed Services University of the Health Sciences · USCentre Hospitalier de l’Université de Montréal · CACenter for Cancer Research · USUniversity of Maryland, Baltimore · USUniversity of Ottawa · CAVeterans Health Administration · US

Funding

Engineering of pan-neutralizing anti-HIV envelope antibodiesR01AI147870 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2020 to 2024
$2.5M
BLRD VA I01 BX005469NIAID NIH HHS R01 AI147870
6 · The paper itself

Abstract

SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019-2020. Viral variants have modified the severity and transmissibility of the disease and continue do so. How much of this change is due to viral fitness versus a response to immune pressure is hard to define. One class of antibodies that continues to afford some level of protection from emerging variants are those that closely overlap the binding site for angiotensin-converting enzyme 2 (ACE2) on the receptor binding domain (RBD). Some members of this class that were identified early in the course of the pandemic arose from the V

Indexed as

Blood Group AntigensCOVID-19AntibodiesHumansMultigene FamilyPandemicsSARS-CoV-2AntibodiesBlood Group Antigensneutralizing antibodyreceptor binding domain (RBD)SARS-CoV-2variants of concern (VOC)VH 3-53 germline gene (IGHV3-53*01)

Identifiers

PMID37334379
PMCPMC10272436
OpenAlexW4379230557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.